Thermo Fisher Scientific Inc

Thermo Fisher’s $3.8 B senior‑notes raise fuels expansion, R&D, and strategic M&A, strengthening its edge in a competitive life‑sciences market.

Thermo Fisher Scientific’s strong earnings, strategic focus on high‑growth cell‑separation and CRISPR markets, disciplined capital allocation, and proactive M&A keep it a top institutional‑investor choice for long‑term life‑science growth.

Thermo Fisher Scientific’s robust $12.3 B revenue surge, strong cash flow, and AI‑driven diagnostic strategy position it for long‑term growth amid evolving genomic data‑privacy rules.

Thermo Fisher Scientific’s strong growth, diversified life‑science tools and robust finances make it a top pick for investors seeking long‑term returns.

Thermo Fisher’s new TetraScience and NVIDIA AI collaborations boost lab‑to‑cloud data, slash costs and drive 4‑5% revenue lift, positioning the company ahead of patent cliffs and competitor AI race.

Thermo Fisher Scientific stays a top choice for life‑sciences investors: strong margins, broad customer base, and strategic acquisitions fuel growth in drug development and precision medicine.

Thermo Fisher’s Jan 29 earnings call will reveal how its AI‑driven instruments, consumables and services adapt to regulatory shifts, competitive pressure and rising R&D spend – a deep dive into its next‑phase growth strategy.

Thermo Fisher’s Q1 2026 earnings call will reveal how its leading PCR, NGS and live‑cell imaging platforms drive revenue and support drug discovery and regulatory success.

Thermo Fisher Scientific tops earnings expectations, boosting shares as its single‑use bioprocessing line and clinical‑trial tools drive growth in cell‑ and gene‑therapy markets.

Thermo Fisher’s 2023 revenue grew 9.8%, EBITDA up 14.3%, and R&D spending hits 8.1% of sales—fueling a 2026 $1.2 B genomic‑sequencing revenue push that outpaces rivals.